// App-Quantinova.ai

P3-09-05 : Clinical outcome of patients with advanced triple negative breast cancer with germline and somatic variants in homologous recombination gene

Researchers

Presenter

  • N Stjepanovic

Principal Investigators

  • M Wilson

  • V Mandilaras

  • H Berman

  • E Amir

  • D Cescon

  • C Elser

  • S Randall Armel

  • J McCuaig

  • A Volenik

  • R Demsky

  • H Chow

  • M Misyura

  • L Wang

  • AM Oza

  • S Kamel-Reid

  • T Stockley

  • PL Bedard

Medical Centers

  • Princess Margaret Cancer Center, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

  • Fanconi anemia, complementation group A

Biomarkers

  • Breast cancer type 1 susceptibility protein

  • Breast cancer type 2 susceptibility protein

  • Fanconi anaemia, complementation group A

  • Transthyretin

  • Tumor protein p53

Drug/Treatment

  • TP53

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01505400

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved